TY - JOUR
T1 - Pazopanib in Patients with Osteosarcoma Metastatic to the Lung
T2 - Phase 2 Study Results and the Lessons for Tumor Measurement
AU - Frankel, Paul
AU - Ruel, Chris
AU - Uche, An
AU - Choy, Edwin
AU - Okuno, Scott
AU - Somiah, Neeta
AU - Chow, Warren A.
N1 - Publisher Copyright:
© 2022 Paul Frankel et al.
PY - 2022
Y1 - 2022
N2 - Background. This single-arm, multicenter, phase 2 study evaluated the safety and antitumor activity of pazopanib in patients with unresectable, pulmonary metastatic osteosarcoma. Patients and Methods. Patients with pulmonary metastatic osteosarcoma unresponsive to chemotherapy were eligible. Patients who received prior tyrosine kinase inhibitor therapy were excluded. Pazopanib at 800 mg once daily was administered for 28-day cycles. Tumor responses were evaluated by local radiology assessment 1 month prior to and after initiation of treatment to calculate tumor doubling time and after every even numbered cycle. The primary endpoints were progression-free survival at 4 months, concomitant with a demonstrated 30% increase in tumor doubling time relative to the pretreatment growth rate. Results. 12 patients (7 female) were enrolled. The study was terminated prematurely due to withdrawal of financial support by the sponsor. 8 subjects were eligible for the primary analysis, whereas 4 patients were in a predefined exploratory "slow-growing"cohort. In the "fast-growing"cohort, 3 of the 8 patients (37.5%) eligible for first-stage analysis were deemed "success"by the preplanned criteria, adequate to proceed to second-stage accrual. In addition, 1 of the 4 patients in the "slow-growing"cohort experienced a partial remission. Grade 1-2 diarrhea was the most common adverse event, and grade 3 events were infrequent. Conclusion. This study illustrates a novel method of demonstrating positive drug activity in osteosarcoma by increasing tumor doubling time, and this is further supported by a partial response in a patient with "slow-growing"disease. This trial is registered with NCT01759303.
AB - Background. This single-arm, multicenter, phase 2 study evaluated the safety and antitumor activity of pazopanib in patients with unresectable, pulmonary metastatic osteosarcoma. Patients and Methods. Patients with pulmonary metastatic osteosarcoma unresponsive to chemotherapy were eligible. Patients who received prior tyrosine kinase inhibitor therapy were excluded. Pazopanib at 800 mg once daily was administered for 28-day cycles. Tumor responses were evaluated by local radiology assessment 1 month prior to and after initiation of treatment to calculate tumor doubling time and after every even numbered cycle. The primary endpoints were progression-free survival at 4 months, concomitant with a demonstrated 30% increase in tumor doubling time relative to the pretreatment growth rate. Results. 12 patients (7 female) were enrolled. The study was terminated prematurely due to withdrawal of financial support by the sponsor. 8 subjects were eligible for the primary analysis, whereas 4 patients were in a predefined exploratory "slow-growing"cohort. In the "fast-growing"cohort, 3 of the 8 patients (37.5%) eligible for first-stage analysis were deemed "success"by the preplanned criteria, adequate to proceed to second-stage accrual. In addition, 1 of the 4 patients in the "slow-growing"cohort experienced a partial remission. Grade 1-2 diarrhea was the most common adverse event, and grade 3 events were infrequent. Conclusion. This study illustrates a novel method of demonstrating positive drug activity in osteosarcoma by increasing tumor doubling time, and this is further supported by a partial response in a patient with "slow-growing"disease. This trial is registered with NCT01759303.
UR - http://www.scopus.com/inward/record.url?scp=85123796301&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123796301&partnerID=8YFLogxK
U2 - 10.1155/2022/3691025
DO - 10.1155/2022/3691025
M3 - Article
AN - SCOPUS:85123796301
SN - 1687-8450
VL - 2022
JO - Journal of Oncology
JF - Journal of Oncology
M1 - 3691025
ER -